Spearhead Capital Advisors, LLC Vertex Pharmaceuticals Inc Transaction History

Spearhead Capital Advisors, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 28, 2022	SELL	$221.42 - $260.97 $441,954 - $520,896	-1,996 Closed	0 $0
Q4 2021 Jan 25, 2022	BUY	$177.01 - $223.45 $2,655 - $3,351	15 Added 0.76%	1,996 $438,000
Q3 2021 Oct 27, 2021	BUY	$181.39 - $202.99 $362 - $405	2 Added 0.1%	1,981 $359,000
Q2 2021 Aug 10, 2021	BUY	$187.49 - $221.1 $46,497 - $54,832	248 Added 14.33%	1,979 $399,000
Q1 2021 Apr 28, 2021	BUY	$207.02 - $241.31 $153,815 - $179,293	743 Added 75.2%	1,731 $372,000
Q4 2020 Feb 02, 2021	BUY	$207.01 - $276.09 $10,971 - $14,632	53 Added 5.67%	988 $234,000
Q3 2020 Oct 16, 2020	BUY	$255.65 - $303.1 $16,872 - $20,004	66 Added 7.59%	935 $254,000
Q2 2020 Jul 16, 2020	BUY	$225.48 - $295.8 $195,942 - $257,050	869 New	869 $252,000

1,716

225M

1.19M

1.56M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Spearhead Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Spearhead Capital Advisors, LLC with notifications on news.